1. Home
  2. ZYME vs RCAT Comparison

ZYME vs RCAT Comparison

Compare ZYME & RCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • RCAT
  • Stock Information
  • Founded
  • ZYME 2003
  • RCAT 2002
  • Country
  • ZYME United States
  • RCAT United States
  • Employees
  • ZYME N/A
  • RCAT N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • RCAT Wholesale Distributors
  • Sector
  • ZYME Health Care
  • RCAT Industrials
  • Exchange
  • ZYME Nasdaq
  • RCAT Nasdaq
  • Market Cap
  • ZYME 968.5M
  • RCAT 807.1M
  • IPO Year
  • ZYME 2017
  • RCAT 2017
  • Fundamental
  • Price
  • ZYME $14.81
  • RCAT $8.94
  • Analyst Decision
  • ZYME Buy
  • RCAT Buy
  • Analyst Count
  • ZYME 7
  • RCAT 1
  • Target Price
  • ZYME $20.00
  • RCAT $13.00
  • AVG Volume (30 Days)
  • ZYME 453.7K
  • RCAT 7.6M
  • Earning Date
  • ZYME 08-07-2025
  • RCAT 08-14-2025
  • Dividend Yield
  • ZYME N/A
  • RCAT N/A
  • EPS Growth
  • ZYME N/A
  • RCAT N/A
  • EPS
  • ZYME N/A
  • RCAT N/A
  • Revenue
  • ZYME $122,867,000.00
  • RCAT N/A
  • Revenue This Year
  • ZYME $107.76
  • RCAT $1,023.35
  • Revenue Next Year
  • ZYME $2.35
  • RCAT $88.95
  • P/E Ratio
  • ZYME N/A
  • RCAT N/A
  • Revenue Growth
  • ZYME 95.94
  • RCAT N/A
  • 52 Week Low
  • ZYME $9.03
  • RCAT $2.31
  • 52 Week High
  • ZYME $17.70
  • RCAT $15.27
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 62.78
  • RCAT 47.87
  • Support Level
  • ZYME $13.48
  • RCAT $8.84
  • Resistance Level
  • ZYME $15.35
  • RCAT $10.40
  • Average True Range (ATR)
  • ZYME 0.58
  • RCAT 0.71
  • MACD
  • ZYME 0.10
  • RCAT -0.07
  • Stochastic Oscillator
  • ZYME 80.21
  • RCAT 41.60

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About RCAT Red Cat Holdings Inc.

Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.

Share on Social Networks: